Twitter | Search | |
Search Refresh
Thrombosis Research 9h
, Bruton’s tyrosine kinase inhibitor, show further inhibition of platelet aggregation in blood samples from patients with acute myocardial infarction, receiving dual anti platelet therapy in a dose dependent manner.
Reply Retweet Like
Silvana Novelli Jul 19
The updated results have been published. No doubts that the combination of is convenient. But a large proportion of patients have received ibru and some have acquired mutations. Wait for results.
Reply Retweet Like
Jeff Sharman Jul 14
Most careers are built by getting reliable singles. Doubles are great and triples are rare. Everyone knows when a home run is hit. We just want our fellows to crowd the plate and get hit by a pitch. Glad I ignored and helped write the first in human study
Reply Retweet Like
Toby Eyre Jul 12
Hillmen et al CLARITY trial 53 R/R + (8wk run in pre-ven) Primary endpt MRD at 12m I-V: MRD-ve 53% PB+BM 36% MRD outcome->defined length Rx ORR 89% 51% CR 1 PD at fup 21months I-V ongoing arm of 1L FLAIR trial
Reply Retweet Like
Bachar Samra, MD Jul 13
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Reply Retweet Like
Debra Robertson Apr 1
Tried explaining the patient acces schemes to a couple of colleagues today when the new tablet strengths were announced. Felt like I should change my name to 'Chuckle'!
Reply Retweet Like
OncoTriage Jun 2
plus is an effective oral regimen for first-line treatment of high-risk and older patients with chronic lymphocytic leukemia:
Reply Retweet Like
Joana Koury Dec 3
Nice validation of clinical model in pte treated with . (AHN, I)
Reply Retweet Like
Tom Henry, MBA, RPh, CPh May 9
Things to Know About Ibrutinib – CLL Society
Reply Retweet Like
pankaj dwivedi Mar 22
Reply Retweet Like
Florian Slimano Jul 14
Prevalence of and mutations in a real‑life cohort still on after three years: a group study Great publication in by Dr Quinquenel from
Reply Retweet Like
Clinton Lewis Dec 4
Is dead? OS benefit for in young and old patients + plenary. Important to assess durability and when ibrutinib can be stopped.
Reply Retweet Like
Dr.Alberto Mussetti Feb 20
+ for R/R . Complete MRD responses in 70-80% of patients and low toxicity. Possibly the right companion for CARTS in CLL.
Reply Retweet Like
Thilo J Zander, MD Jun 19
Dr Carl June describes how to optimize CAR-T cell therapy by giving concomitantly in and maybe patients
Reply Retweet Like
CLL Society Inc. Jun 23
Reply Retweet Like
Yüksel Ürün Dec 1
based regimens yield better PFS than Chemoimmunotherapy in Older Patients with Untreated ⁩ ⁦
Reply Retweet Like
Toby Eyre Jun 19
plus ritux induction followed by attenuated cycle number of HyperCvad/MA (4). Impressive responses. Clearly active but why the high dose MTX?
Reply Retweet Like
Bichoy Gabra, R.Ph., Ph.D. Apr 18
Bijal Shah, MD, Center, discusses overcoming resistance to inhibitors in the treatment of ​ Comparing the Inhibitors, and Treatment and Response Assessment for
Reply Retweet Like
Kibar Yared Apr 26
Approach to in those treated with by Dr. Margo Davis stopping ibrutinib doesn’t take away the AF!
Reply Retweet Like
Andrew Slorance Apr 11
After today's cancer update, I've done another blog thing. You read my ramblings here:
Reply Retweet Like